Twist Bioscience Joins Lilly's TuneLab AI Drug Discovery Platform
TWST has more than doubled off its 52-week low of $23.3.
Summary
Twist Bioscience announced an agreement with Lilly TuneLab, Eli Lilly's collaborative AI/ML drug discovery platform, to provide antibody characterization data services, including for AbLab, an antibody developability prediction model. This partnership positions Twist as a key data provider within Lilly's ecosystem, enabling TuneLab users to order antibody services using preferred Twist protocols. The deal follows Twist's recent selection by Anthropic as an independent evaluator for AI-driven protein design, reinforcing its role in AI-enabled drug discovery. The announcement drove TWST shares up 5.79% to $146.09, approaching its 52-week high of $155.44. This partnership could expand Twist's revenue opportunities in the growing AI drug discovery market, though financial terms were not disclosed.
At the time of this announcement, TWST was trading at $144.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.5B. The 52-week trading range was $23.30 to $155.44. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.